Place des inhibiteurs de PARP dans le traitement des cancers de l’endomètre et du col de l’utérus

Gac, Marjolaine Le; Koual, Meriem; Delanoy, Nicolas; Perkins, Géraldine; Nguyen-Xuan, Huyên-Thu; Frère‐Belda, Marie‐Aude Le; Laurent‐Puig, Pierre; Bentivegna, Enrica; Durdux, C.; Azaïs, Henri; Bats, Anne‐Sophie

doi:10.1016/j.bulcan.2021.09.011

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FDA has approved Olaparib for treating recurrent platinum-sensitive ovarian cancer in the germline or somatic BRCA1/2 mutations. Furthermore, PARPi in treating cervical and uterine cancer are under clinical evaluation [14,15]. Rucaparib has been approved by the FDA for the treatment of mCRPC patients with somatic and/or germline DDR alterations who have progressed through enzalutamide or abiraterone treatment.…”

Section: Discussionmentioning

confidence: 99%

Case report: Response with chemotherapy and Olaparib in a patient with advanced cervical adenocarcinoma

Zhuang

Qin

Kou

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Cervical adenocarcinomas are a heterogeneous group of tumors, accounting for approximately 20% of all cervical cancers. Many clinical data suggest that the activity of PARPi inhibitors may not be limited to BRCA mutated tumours and may involve the homologous recombination pathway. At present, there are few data available on the activity of PARPi in endometrial and cervical cancers. And poly-(ADP)-ribose polymerase inhibitors (PARPi) are changing clinical practice in the BRCA mutant patients with cervical cancer. Case Description: Here, we report the case of a 66-year-old female patient admitted to the hospital due to abnormal vaginal bleeding. She was diagnosed with advanced cervical adenocarcinomas, and received chemotherapy followed by Paclitaxe and Cisplatin in the first-line. However, after one cycle of treatment, the patient's disease progressed. To identify more opportunities for treatment, the biopsy tissue was genetic tested and found BRCA1 exon 23 mutation and PD-L1 positive score, which motivated chemotherapy combined with immune checkpoint inhibitors, and the tumor size decreased. However, because of the side effects of from long-term chemotherapy, the patient chosen Olaparib treatment in the later stage. The patient benefited long-term disease control for about 24 months. Conclusions: This case might support the strategy that PARPi could be an alternative treatment for cervical adenocarcinoma patients with BRCA1 mutation in the future.

show abstract

Section: Discussionmentioning

confidence: 99%